Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic
TL;DR
Aditxt's subsidiary Pearsanta offers investors early access to a novel blood test that could disrupt the $10B endometriosis market with non-invasive diagnostics.
Pearsanta's clinical study compares the Mitomic Endometriosis Test against laparoscopic diagnosis across 1,000 participants to validate its accuracy through systematic data collection.
This non-invasive blood test enables earlier endometriosis detection, reducing surgical risks and improving women's health outcomes through accessible diagnostic innovation.
Aditxt's blood test detects endometriosis markers years before symptoms appear, revolutionizing women's healthcare with cutting-edge molecular diagnostics.
Found this article helpful?
Share it with your network and spread the knowledge!
Aditxt Inc. (NASDAQ: ADTX) announced that its subsidiary Pearsanta Inc. has initiated enrollment in a prospective clinical study evaluating the Mitomic Endometriosis Test (MET), a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET's performance to laparoscopic diagnosis, the current gold standard, across up to 1,000 participants referred for surgery.
The first enrollment site, Dedicated to Women OB/GYN in Dover, Delaware, has begun recruiting participants for the clinical validation study. Pearsanta President Chris Mitton described the enrollment milestone as supporting validation of a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis.
This development represents a significant advancement in women's healthcare, as endometriosis currently affects approximately 10% of reproductive-aged women worldwide. The condition, where tissue similar to the uterine lining grows outside the uterus, often takes 7-10 years to diagnose using current methods. The lengthy diagnostic process contributes to delayed treatment and prolonged patient suffering.
The blood-based test being studied offers potential advantages over the current diagnostic standard of laparoscopic surgery, which requires general anesthesia and carries surgical risks. A non-invasive blood test could provide earlier detection, reduce healthcare costs, and improve patient access to timely diagnosis and treatment.
Aditxt operates as a social innovation platform advancing health innovations across multiple programs, including women's health, autoimmunity, cancer and early disease detection, and infectious diseases. The company's latest news and updates relating to ADTX are available in the company's newsroom at https://ibn.fm/ADTX. The full press release detailing the clinical study initiation can be viewed at https://ibn.fm/WiIhM.
The successful validation of the MET test could have substantial implications for the healthcare industry and women's health diagnostics market. Earlier detection of endometriosis could lead to more effective management of symptoms, reduced disease progression, and improved quality of life for millions of women worldwide. The study's outcomes will be closely watched by healthcare providers, investors, and patients seeking less invasive diagnostic options for this common but often misunderstood condition.
Curated from InvestorBrandNetwork (IBN)
